Vancouver, British Columbia — December 17, 2025 — Leads & Copy — DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) has signed a non-binding term sheet with Sheba Impact, the Technology Transfer office (“TTO”) of Sheba Medical Center (“Sheba MC”), Israel’s largest hospital and one of the world’s most innovative clinical research institutions, and with Ramot, the TTO of Tel Aviv University (“TAU”), Israel’s largest University, to exclusively license technology co-developed at Sheba Medical Center and TAU.
The term sheet outlines DiagnosTear’s intention to exclusively license the “CLARIFY” technology, an imaging platform designed to perform blood counts and analyze blood related parameters directly through imaging of the blood vessels in the eye surface. The terms of the license are to be finalized in a definitive agreement.
The CLARIFY technology was developed by Prof. Haim Suchowski at TAU, and Prof. Ygal Rotenstreich at Sheba MC, who first demonstrated the feasibility of scleral vascular imaging in an Israeli space mission focused on non-invasive blood assessment in microgravity. DiagnosTear aims to advance the technology into a clinically validated, commercially ready solution leveraging spectral imaging of the scleral vasculature and proprietary algorithms to measure blood components such as red blood cells, white blood cells, hemoglobin-related indicators, and inflammatory signatures, without the need for a traditional blood draw. The goal is to provide rapid, painless, and accessible diagnostics for chronic care and emergency settings.
According to Dr. Shimon Gross, CEO of DiagnosTear, this potential collaboration represents a major step in bringing CLARIFY closer to patients. He stated that working together with Sheba MC and TAU, which are ranked among the world’s top respected clinical research hubs, will allow the company to accelerate clinical evaluation of this novel technology and explore its potential to transform routine patient care. He added that this opportunity is synergistic with the markets, users and the regulatory requirements in which the company is operating.
Under the provisions of the term sheet, the parties intend to finalize a comprehensive research and licensing agreement that will include a structured clinical development plan and defined pathways for product evaluation and future commercialization. The term sheet is non-binding and serves as a framework for formalizing the definitive agreement.
Dr. Avital Beck, Business Development Manager at DiagnosTear, said that CLARIFY has the potential to redefine how frequent blood monitoring is performed and that a needle free, rapid, and accurate method could significantly improve both patient comfort and clinical decision making.
The company will provide additional updates once the definitive license agreement is signed and as key milestones are achieved.
DiagnosTear is a medical diagnostics company developing rapid, point-of-care, multi-parameter tests for ocular conditions. By leveraging the diagnostic potential of tear and scleral imaging, the Company provides solutions that help clinicians detect and differentiate Dry Eye, Red Eye, and blood-related conditions.
DiagnosTear Technologies Inc.
Email: info@diagnostear.com
Source: DiagnosTear
